8 research outputs found
Role of Microenvironment in Ovarian Tumourisation
Background. Metastasis is a formidable complication of malignant neoplasms, with therapy not always effective in advanced malignancy. Metastasis is a multistep process involving the cancer cell detachment from primary tumour, intravasation, extravasation and invasion into the target organ. Early metastasis stages are well understood, whilst the impact of tumour microenvironment on the disease progression and advancement remains a matter of debate.Aim. An immunohistochemical study of the adaptive and reactive properties of greater omentum with metastatic involvement in ovarian cancer.Materials and methods. We examined greater omentum tissue samples from 40 patients with verifi ed stage 3a and b ovarian cancers. For light microscopy, samples were fi xed in 10Β % formalin, dehydrated, paraffi n-embedded and stained with Mayerβs haematoxylin and eosin. Immunohistochemical assays used monoclonal antibodies against CD7, CD4, CD8, CD 68, VEGF, D2-40 and CD44 proteins. Statistical data analysis was performed with Statistica v. 7.0 soft ware.Results and discussion. Analyses of the greater omentum tissues revealed cases of leucocyte-bank encapsulation of metastatic foci. Higher CD7+ and CD8+ cell counts were observed in encapsulation, possibly influencing the greater omentum reactive and adaptive properties. Higher CD44-expressing cell counts were also detected in greater omentum samples lacking encapsulation. Angiogenesis marker-expressing cells (e.g., VEGF and CD34) predominated in greater omentum tissues lacking leucocyte-bank encapsulation of metastatic foci.Conclusion. Events in tumour microenvironment may be indicative of a preserved or reduced organ adaptivity, the latter facilitating disease progression
Π ΠΎΠ»Ρ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ Π² ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
Background. Metastasis is a formidable complication of malignant neoplasms, with therapy not always effective in advanced malignancy. Metastasis is a multistep process involving the cancer cell detachment from primary tumour, intravasation, extravasation and invasion into the target organ. Early metastasis stages are well understood, whilst the impact of tumour microenvironment on the disease progression and advancement remains a matter of debate.Aim. An immunohistochemical study of the adaptive and reactive properties of greater omentum with metastatic involvement in ovarian cancer.Materials and methods. We examined greater omentum tissue samples from 40 patients with verifi ed stage 3a and b ovarian cancers. For light microscopy, samples were fi xed in 10Β % formalin, dehydrated, paraffi n-embedded and stained with Mayerβs haematoxylin and eosin. Immunohistochemical assays used monoclonal antibodies against CD7, CD4, CD8, CD 68, VEGF, D2-40 and CD44 proteins. Statistical data analysis was performed with Statistica v. 7.0 soft ware.Results and discussion. Analyses of the greater omentum tissues revealed cases of leucocyte-bank encapsulation of metastatic foci. Higher CD7+ and CD8+ cell counts were observed in encapsulation, possibly influencing the greater omentum reactive and adaptive properties. Higher CD44-expressing cell counts were also detected in greater omentum samples lacking encapsulation. Angiogenesis marker-expressing cells (e.g., VEGF and CD34) predominated in greater omentum tissues lacking leucocyte-bank encapsulation of metastatic foci.Conclusion. Events in tumour microenvironment may be indicative of a preserved or reduced organ adaptivity, the latter facilitating disease progression.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠ°ΡΡΠ°Π·Ρ ΡΠ²Π»ΡΡΡΡΡ Π³ΡΠΎΠ·Π½ΡΠΌ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠ΅ΠΌ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΈΒ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π²Β Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°. ΠΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅Β β ΠΌΠ½ΠΎΠ³ΠΎΡΡΠ°ΠΏΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΠΉ Π²Β ΡΠ΅Π±Ρ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΎΡΒ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΈΠ½ΡΡΠ°Π²Π°Π·Π°ΡΠΈΡ, ΡΠΊΡΡΡΠ°Π²Π°Π·Π°ΡΠΈΡ ΠΈΒ ΠΈΠ½Π²Π°Π·ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ Π²Β ΠΎΡΠ³Π°Π½-ΠΌΠΈΡΠ΅Π½Ρ. Π Π°Π½Π½ΠΈΠ΅ ΡΡΠ°ΠΏΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Ρ
ΠΎΡΠΎΡΠΎ ΠΈΠ·ΡΡΠ΅Π½Ρ. ΠΠΎΠΏΡΠΎΡ ΠΎΒ ΡΠΎΠΌ, ΠΊΠ°ΠΊ Π²Π»ΠΈΡΠ΅Ρ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π°Β ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΒ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄ΠΈΡΠΊΡΡΡΠΈΠΎΠ½Π½ΡΠΌ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π°Π΄Π°ΠΏΡΠΈΠ²Π½ΡΡ
ΠΈΒ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠ°Π»ΡΠ½ΠΈΠΊΠ° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² ΡΒ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠ°Π»ΡΠ½ΠΈΠΊΠ° Π½Π°Β ΠΎΡΠ½ΠΎΠ²Π΅ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈΒ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΡΠΊΠ°Π½Π΅ΠΉ Π±ΠΎΠ»ΡΡΠΈΡ
ΡΠ°Π»ΡΠ½ΠΈΠΊΠΎΠ² 40Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΡΒ Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²Β III a ΠΈΒ b ΡΡΠ°Π΄ΠΈΠΉ. ΠΒ ΡΠ°Π±ΠΎΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΠΌΠ΅ΡΠΎΠ΄Ρ ΡΠ²Π΅ΡΠΎΠ²ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΠΈ, ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π»ΠΈ Π²Β 10Β % ΡΠ°ΡΡΠ²ΠΎΡΠ΅ ΡΠΎΡΠΌΠ°Π»ΠΈΠ½Π°, ΠΎΠ±Π΅Π·Π²ΠΎΠΆΠΈΠ²Π°Π»ΠΈ ΠΈΒ Π·Π°Π»ΠΈΠ²Π°Π»ΠΈ Π²Β ΠΏΠ°ΡΠ°ΡΠΈΠ½, ΠΎΠΊΡΠ°ΡΠΊΠ° Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΠΈΠ½ΠΎΠΌ ΠΠ°ΠΉΠ΅ΡΠ° ΠΈΒ ΡΠΎΠ·ΠΈΠ½ΠΎΠΌ. ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ ΡΒ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΊΒ Π±Π΅Π»ΠΊΠ°ΠΌ CD7, CD4, CD8, CD 68, VEGF, D2β40, CD44. ΠΠ»Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ Π΄Π°Π½Π½ΡΡ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π»ΠΈΡΠ΅Π½Π·ΠΈΠΎΠ½Π½ΡΠΉ ΠΏΠ°ΠΊΠ΅Ρ ΠΏΡΠΈΠΊΠ»Π°Π΄Π½ΡΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ Statistica 7.0.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΒ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΒ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΊΠ°Π½Π΅ΠΉ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠ°Π»ΡΠ½ΠΈΠΊΠ° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ, ΡΡΠΎ Π²Β Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
ΡΠ»ΡΡΠ°ΡΡ
ΡΠΎΡΠΌΠΈΡΡΠ΅ΡΡΡ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΡΠΉ Π²Π°Π» Π²ΠΎΠΊΡΡΠ³ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ°Π³Π°. ΠΒ ΡΠΎΡΡΠ°Π²Π΅ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ Π²Π°Π»Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ Π±ΠΎΠ»ΡΡΠ΅Π΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ CD7+ ΠΈΒ CD8+ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΡΠΎ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ, Π²Π»ΠΈΡΠ»ΠΎ Π½Π°Β ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΠΈΒ Π°Π΄Π°ΠΏΡΠΈΠ²Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠ°Π»ΡΠ½ΠΈΠΊΠ°. Π’Π°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΡ
CD44Β Π²Β ΡΠ΅Ρ
ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
Π±ΠΎΠ»ΡΡΠΈΡ
ΡΠ°Π»ΡΠ½ΠΈΠΊΠΎΠ², Π³Π΄Π΅ ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π» Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΡΠΉ Π²Π°Π». ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΡ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π°, ΡΠ°ΠΊΠΈΠ΅ ΠΊΠ°ΠΊΒ VEGF, CD34, ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΎ Π²Β ΡΠΊΠ°Π½ΡΡ
Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠ°Π»ΡΠ½ΠΈΠΊΠ° Π±Π΅Π· Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ³ΠΎ Π²Π°Π»Π° Π²ΠΎΠΊΡΡΠ³ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ°Π³Π°. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΒ ΡΠΊΠ°Π½ΡΡ
ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΌΠΎΠ³ΡΡ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΠ΅ Π½Π°Β ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π°Π΄Π°ΠΏΡΠΈΠ²Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΠΎΡΠ³Π°Π½Π°, ΡΡΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΌΡ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ